Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 84 articles:
HTML format
Text format



Single Articles


    February 2017
  1. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    BMC Cancer. 2017;17:97.
    PubMed     Text format     Abstract available


    January 2017
  2. MIYAMOTO S, Yotsumoto F, Ueda T, Fukami T, et al
    BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
    BMC Cancer. 2017;17:89.
    PubMed     Text format     Abstract available


  3. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Text format     Abstract available


  4. AYYAGARI VN, Hsieh TJ, Diaz-Sylvester PL, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    BMC Cancer. 2017;17:49.
    PubMed     Text format     Abstract available


  5. BRANDT S, Samartzis EP, Zimmermann AK, Fink D, et al
    Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    BMC Cancer. 2017;17:44.
    PubMed     Text format     Abstract available


  6. TEMPFER CB, Hartmann F, Hilal Z, Rezniczek GA, et al
    Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.
    BMC Cancer. 2017;17:26.
    PubMed     Text format     Abstract available


    December 2016
  7. MAISTRO S, Teixeira N, Encinas G, Katayama ML, et al
    Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    BMC Cancer. 2016;16:934.
    PubMed     Text format     Abstract available


    November 2016
  8. NAKAMURA H, Nagasaka K, Kawana K, Taguchi A, et al
    Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
    BMC Cancer. 2016;16:897.
    PubMed     Text format     Abstract available


  9. YU X, Zhang Y, Chen H
    LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    BMC Cancer. 2016;16:846.
    PubMed     Text format     Abstract available


    October 2016
  10. YE H, Liu X, Sun J, Zhu S, et al
    Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
    BMC Cancer. 2016;16:831.
    PubMed     Text format     Abstract available


  11. ORNELAS A, McCullough CR, Lu Z, Zacharias NM, et al
    Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
    BMC Cancer. 2016;16:824.
    PubMed     Text format     Abstract available


    February 2016
  12. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Text format     Abstract available


    January 2016
  13. FENG Z, Wen H, Bi R, Duan Y, et al
    Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    BMC Cancer. 2016;16:43.
    PubMed     Text format     Abstract available


  14. SCHMID G, Notaro S, Reimer D, Abdel-Azim S, et al
    Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    BMC Cancer. 2016;16:102.
    PubMed     Text format     Abstract available


  15. WU GJ, Zeng GF
    METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
    BMC Cancer. 2016;16:136.
    PubMed     Text format     Abstract available


  16. KOUSSOUNADIS A, Langdon SP, Um I, Kay C, et al
    Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    BMC Cancer. 2016;16:205.
    PubMed     Text format     Abstract available


  17. HIJAZ M, Das S, Mert I, Gupta A, et al
    Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
    BMC Cancer. 2016;16:220.
    PubMed     Text format     Abstract available


  18. ZHOU J, Zhao M, Tang Y, Wang J, et al
    The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.
    BMC Cancer. 2016;16:246.
    PubMed     Text format     Abstract available


  19. STAUDIGL C, Pfeiler G, Hrauda K, Renz R, et al
    Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
    BMC Cancer. 2016;16:436.
    PubMed     Text format     Abstract available


  20. SAMARDZIJA C, Luwor RB, Quinn MA, Kannourakis G, et al
    Coalition of Oct4A and beta1 integrins in facilitating metastasis in ovarian cancer.
    BMC Cancer. 2016;16:432.
    PubMed     Text format     Abstract available


  21. XIAO X, Yang G, Bai P, Gui S, et al
    Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    BMC Cancer. 2016;16:582.
    PubMed     Text format     Abstract available


  22. COZZI GD, Samuel JM, Fromal JT, Keene S, et al
    Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
    BMC Cancer. 2016;16:612.
    PubMed     Text format     Abstract available


  23. KIM MK, Caplen N, Chakka S, Hernandez L, et al
    Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
    BMC Cancer. 2016;16:678.
    PubMed     Text format     Abstract available


  24. BLOK F, Roes EM, van Leenders GJ, van Beekhuizen HJ, et al
    The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    BMC Cancer. 2016;16:18.
    PubMed     Text format     Abstract available


  25. PARK B, Park S, Shin HR, Shin A, et al
    Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea.
    BMC Cancer. 2016;16:5.
    PubMed     Text format     Abstract available


  26. LI X, Shen B, Chen Q, Zhang X, et al
    Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    BMC Cancer. 2016;16:251.
    PubMed     Text format     Abstract available


  27. CHANG YH, Li WH, Chang Y, Peng CW, et al
    Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    BMC Cancer. 2016;16:235.
    PubMed     Text format     Abstract available


    May 2015
  28. MACKENZIE R, Kommoss S, Winterhoff BJ, Kipp BR, et al
    Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    BMC Cancer. 2015;15:415.
    PubMed     Text format     Abstract available


    April 2015
  29. ORELLANA R, Kato S, Erices R, Bravo ML, et al
    Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells.
    BMC Cancer. 2015;15:290.
    PubMed     Text format     Abstract available


  30. QIAN Q, You Y, Yang J, Cao D, et al
    Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study.
    BMC Cancer. 2015;15:270.
    PubMed     Text format     Abstract available


  31. CABURET S, Anttonen M, Todeschini AL, Unkila-Kallio L, et al
    Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes.
    BMC Cancer. 2015;15:251.
    PubMed     Text format     Abstract available


    March 2015
  32. JOZWIK M, Okungbowa OE, Lipska A, Jozwik M, et al
    Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies.
    BMC Cancer. 2015;15:129.
    PubMed     Text format     Abstract available


    February 2015
  33. CHUFFA L, Fioruci-Fontanelli BA, Mendes LO, Ferreira Seiva FR, et al
    Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.
    BMC Cancer. 2015;15:34.
    PubMed     Text format     Abstract available


    January 2015
  34. LIUTKAUSKIENE S, Janciauskiene R, Jureniene K, Grizas S, et al
    Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    BMC Cancer. 2015;15:1104.
    PubMed     Text format     Abstract available


  35. LEE JY, Yoon JK, Kim B, Kim S, et al
    Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    BMC Cancer. 2015;15:1077.
    PubMed     Text format     Abstract available


  36. LLOYD KL, Cree IA, Savage RS
    Prediction of resistance to chemotherapy in ovarian cancer: a systematic review.
    BMC Cancer. 2015;15:117.
    PubMed     Text format     Abstract available


  37. KIM MK, James J, Annunziata CM
    Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
    BMC Cancer. 2015;15:196.
    PubMed     Text format     Abstract available


  38. LEE JY, Yoon JK, Kim B, Kim S, et al
    Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    BMC Cancer. 2015;15:85.
    PubMed     Text format     Abstract available


  39. LIUTKAUSKIENE S, Janciauskiene R, Jureniene K, Grizas S, et al
    Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    BMC Cancer. 2015;15:105.
    PubMed     Text format     Abstract available


  40. PYLVAS-EEROLA M, Karihtala P, Puistola U
    Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    BMC Cancer. 2015;15:493.
    PubMed     Text format     Abstract available


  41. MEYS EM, Rutten IJ, Kruitwagen RF, Slangen BF, et al
    Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlan
    BMC Cancer. 2015;15:482.
    PubMed     Text format     Abstract available


  42. MCEVOY LM, O'Toole SA, Spillane CD, Martin CM, et al
    Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    BMC Cancer. 2015;15:547.
    PubMed     Text format     Abstract available


  43. REN Y, Jiang R, Yin S, You C, et al
    Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
    BMC Cancer. 2015;15:583.
    PubMed     Text format     Abstract available


  44. COOKE NM, Spillane CD, Sheils O, O'Leary J, et al
    Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
    BMC Cancer. 2015;15:627.
    PubMed     Text format     Abstract available


  45. SUN F, Ding W, He JH, Wang XJ, et al
    Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    BMC Cancer. 2015;15:746.
    PubMed     Text format     Abstract available


  46. REFKY B, Kotb S, Fady T, Marwan A, et al
    Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study.
    BMC Cancer. 2015;15:754.
    PubMed     Text format     Abstract available


  47. JATOI A, Foster NR, Kalli KR, Vierkant RA, et al
    Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.
    BMC Cancer. 2015;15:711.
    PubMed     Text format     Abstract available


  48. ARSENIC R, Braicu EI, Letsch A, Dietel M, et al
    Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
    BMC Cancer. 2015;15:784.
    PubMed     Text format     Abstract available


  49. ZHOU C, Kang J, Wang X, Wei W, et al
    Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models.
    BMC Cancer. 2015;15:889.
    PubMed     Text format     Abstract available


  50. FOURCADIER E, Tretarre B, Gras-Aygon C, Ecarnot F, et al
    Under-treatment of elderly patients with ovarian cancer: a population based study.
    BMC Cancer. 2015;15:937.
    PubMed     Text format     Abstract available


  51. YAO X, Dong Z, Zhang Q, Wang Q, et al
    Epithelial ovarian cancer stem-like cells expressing alpha-gal epitopes increase the immunogenicity of tumor associated antigens.
    BMC Cancer. 2015;15:956.
    PubMed     Text format     Abstract available


  52. CUI X, Li L, Yan G, Meng K, et al
    High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    BMC Cancer. 2015;15:244.
    PubMed     Text format     Abstract available


  53. CHEN J, Liu Z, Fang S, Fang R, et al
    Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
    BMC Cancer. 2015;15:91.
    PubMed     Text format     Abstract available


  54. CAO WM, Gao Y, Yang HJ, Xie SN, et al
    Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    BMC Cancer. 2016;16:64.
    PubMed     Text format     Abstract available


  55. LANE D, Matte I, Garde-Granger P, Laplante C, et al
    Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    BMC Cancer. 2015;15:492.
    PubMed     Text format     Abstract available


  56. CHEN S, Gou WF, Zhao S, Niu ZF, et al
    The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.
    BMC Cancer. 2015;15:471.
    PubMed     Text format     Abstract available


  57. ZHANG Y, Fan S, Xiang Y, Duan H, et al
    Comparison of the prognosis and recurrence of apparent early-stage ovarian tumors treated with laparoscopy and laparotomy: a meta-analysis of clinical studies.
    BMC Cancer. 2015;15:597.
    PubMed     Text format     Abstract available


  58. LI X, Pan Q, Wan X, Mao Y, et al
    Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    BMC Cancer. 2015;15:509.
    PubMed     Text format     Abstract available


  59. HEMPEN A, Samartzis EP, Kamarachev J, Fink D, et al
    Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.
    BMC Cancer. 2015;15:507.
    PubMed     Text format     Abstract available


  60. HUANG R, Li X, Holm R, Trope CG, et al
    The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.
    BMC Cancer. 2015;15:502.
    PubMed     Text format     Abstract available


  61. DU J, Li B, Fang Y, Liu Y, et al
    Overexpression of Class III beta-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    BMC Cancer. 2015;15:536.
    PubMed     Text format     Abstract available


  62. TRENDOWSKI M, Christen TD, Acquafondata C, Fondy TP, et al
    Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    BMC Cancer. 2015;15:632.
    PubMed     Text format     Abstract available


  63. BURGHAUS S, Haberle L, Schrauder MG, Heusinger K, et al
    Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study.
    BMC Cancer. 2015;15:751.
    PubMed     Text format     Abstract available


  64. HO CM, Huang CJ, Huang SH, Chang SF, et al
    Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
    BMC Cancer. 2015;15:789.
    PubMed     Text format     Abstract available


  65. NISHIMURA T, Nakamura K, Yamashita S, Ikeda S, et al
    Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
    BMC Cancer. 2015;15:957.
    PubMed     Text format     Abstract available


  66. MOTA A, Trivino JC, Rojo-Sebastian A, Martinez-Ramirez A, et al
    Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    BMC Cancer. 2015;15:940.
    PubMed     Text format     Abstract available


    December 2014
  67. TONE AA, McConechy MK, Yang W, Ding J, et al
    Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    BMC Cancer. 2014;14:982.
    PubMed     Text format     Abstract available


  68. FERRANDINA G, Corrado G, Mascilini F, Malaguti P, et al
    Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
    BMC Cancer. 2014;14:947.
    PubMed     Text format     Abstract available


  69. WANG Y, Herrstedt J, Havsteen H, DePoint Christensen R, et al
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    BMC Cancer. 2014;14:937.
    PubMed     Text format     Abstract available


    November 2014
  70. BRANDALIZE AP, Schuler-Faccini L, Hoffmann JS, Caleffi M, et al
    A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.
    BMC Cancer. 2014;14:850.
    PubMed     Text format     Abstract available


  71. PENZVALTO Z, Lanczky A, Lenart J, Meggyeshazi N, et al
    MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
    BMC Cancer. 2014;14:837.
    PubMed     Text format     Abstract available


  72. WANG KC, Chang WH, Lee WL, Huang N, et al
    An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis.
    BMC Cancer. 2014;14:831.
    PubMed     Text format     Abstract available


  73. HIRATA Y, Murai N, Yanaihara N, Saito M, et al
    MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    BMC Cancer. 2014;14:799.
    PubMed     Text format     Abstract available


    September 2014
  74. SEONG MW, Cho SI, Kim KH, Chung IY, et al
    A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients.
    BMC Cancer. 2014;14:645.
    PubMed     Text format     Abstract available


    August 2014
  75. LV H, Shi Y, Zhang L, Zhang D, et al
    Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor.
    BMC Cancer. 2014;14:576.
    PubMed     Text format     Abstract available


  76. BRYANT C, Rawlinson R, Massey AJ
    Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    BMC Cancer. 2014;14:570.
    PubMed     Text format     Abstract available


    July 2014
  77. LONGO R, Platini C, Eid N, Elias-Matta C, et al
    A late, solitary brain metastasis of epithelial ovarian carcinoma.
    BMC Cancer. 2014;14:543.
    PubMed     Text format     Abstract available


  78. GOU WF, Zhao Y, Lu H, Yang XF, et al
    The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells.
    BMC Cancer. 2014;14:477.
    PubMed     Text format     Abstract available


    June 2014
  79. TILLI TM, Bellahcene A, Castronovo V, Gimba ER, et al
    Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.
    BMC Cancer. 2014;14:433.
    PubMed     Text format     Abstract available


    February 2014
  80. WIEGAND KC, Hennessy BT, Leung S, Wang Y, et al
    A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    BMC Cancer. 2014;14:120.
    PubMed     Text format     Abstract available


    January 2014
  81. LIU BL, Liu SJ, Baskys A, Cheng H, et al
    Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
    BMC Cancer. 2014;14:829.
    PubMed     Text format     Abstract available


  82. MATTE I, Lane D, Boivin M, Rancourt C, et al
    MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
    BMC Cancer. 2014;14:234.
    PubMed     Text format     Abstract available


  83. MICCI F, Haugom L, Abeler VM, Davidson B, et al
    Genomic profile of ovarian carcinomas.
    BMC Cancer. 2014;14:315.
    PubMed     Text format     Abstract available


  84. MATTE I, Lane D, Bachvarov D, Rancourt C, et al
    Role of malignant ascites on human mesothelial cells and their gene expression profiles.
    BMC Cancer. 2014;14:288.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: